2IVB logo

Indivior DB:2IVB Stock Report

Last Price

€17.80

Market Cap

€2.4b

7D

-1.7%

1Y

8.0%

Updated

24 Apr, 2024

Data

Company Financials +

2IVB Stock Overview

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.

2IVB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance1/6
Financial Health1/6
Dividends0/6

Indivior PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Indivior
Historical stock prices
Current Share PriceUK£17.80
52 Week HighUK£21.90
52 Week LowUK£13.20
Beta0.018
1 Month Change-7.10%
3 Month Change9.07%
1 Year Change8.01%
3 Year Change119.35%
5 Year Changen/a
Change since IPO221.01%

Recent News & Updates

Recent updates

Shareholder Returns

2IVBDE PharmaceuticalsDE Market
7D-1.7%3.2%1.7%
1Y8.0%-28.2%2.3%

Return vs Industry: 2IVB exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.

Return vs Market: 2IVB exceeded the German Market which returned 2.2% over the past year.

Price Volatility

Is 2IVB's price volatile compared to industry and market?
2IVB volatility
2IVB Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement6.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2IVB has not had significant price volatility in the past 3 months.

Volatility Over Time: 2IVB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20141,164Mark Crossleywww.indivior.com

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.

Indivior PLC Fundamentals Summary

How do Indivior's earnings and revenue compare to its market cap?
2IVB fundamental statistics
Market cap€2.39b
Earnings (TTM)€1.87m
Revenue (TTM)€1.02b

1,278x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2IVB income statement (TTM)
RevenueUS$1.09b
Cost of RevenueUS$186.00m
Gross ProfitUS$907.00m
Other ExpensesUS$905.00m
EarningsUS$2.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)0.015
Gross Margin82.98%
Net Profit Margin0.18%
Debt/Equity Ratio0.0%

How did 2IVB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.